Following this purchase, Duggan now directly owns 42,328,717 shares of the company. Additionally, he maintains indirect ownership through affiliated companies, holding 561,089 shares via Genius 24C Inc. and 400,877 shares through Blazon Corporation. Duggan's increased investment underscores his continued confidence in Pulse Biosciences (NASDAQ:PLSE), a company known for its innovative medical instruments and apparatus. InvestingPro analysis indicates the company maintains good overall financial health, though current valuations suggest the stock may be trading above its Fair Value. InvestingPro subscribers have access to 12 additional valuable insights about PLSE, including detailed financial health metrics and growth projections. Get the full picture with the comprehensive Pro Research Report, available exclusively on InvestingPro. InvestingPro analysis indicates the company maintains good overall financial health, though current valuations suggest the stock may be trading above its Fair Value. InvestingPro subscribers have access to 12 additional valuable insights about PLSE, including detailed financial health metrics and growth projections. Get the full picture with the comprehensive Pro Research Report, available exclusively on InvestingPro.
Following this purchase, Duggan now directly owns 42,328,717 shares of the company. Additionally, he maintains indirect ownership through affiliated companies, holding 561,089 shares via Genius 24C Inc. and 400,877 shares through Blazon Corporation. Duggan's increased investment underscores his continued confidence in Pulse Biosciences, a company known for its innovative medical instruments and apparatus.
In other recent news, Pulse Biosciences has been undergoing significant changes and developments. The medical device company recently announced the departure of its President and CEO, Mr. Burke T. Barrett. The interim leadership will be taken over by Kevin P. Danahy, the Chief Commercial Officer, and Darrin R. Uecker, the Chief Technology Officer.
In addition, the company disclosed that major stockholder and Co-Chairman Robert W. Duggan is considering substantial market purchases of the company's common stock. This could potentially signal an increased investment in Pulse Biosciences.
On the financial front, despite recording a GAAP net loss of $12.7 million for Q3 2024, Pulse Biosciences successfully raised $60 million through a rights offering, ending the quarter with $79 million in cash and cash equivalents.
The company has also been progressing in its technological developments. Preliminary results from a feasibility study on its Nanosecond Pulsed Field Ablation (nano-PFA) technology indicate the technology's potential in reducing benign thyroid nodules and providing symptomatic relief. Furthermore, Pulse Biosciences treated its first Atrial Fibrillation patients in Europe using the nano-PFA Cardiac Surgical System, which has received U.S. FDA breakthrough device designation.
These are just some of the recent developments at Pulse Biosciences, indicating an active period for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.